Cited by 562Retinal Diseases and TreatmentsRetinal and Macular SurgeryOcular Diseases and Behçet’s Syndrome

The DOI matches its Crossref record; 9 of the 10 references it cites were found in a registry or an index.

Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: 5-Year Randomized Trial Results

Open access

Elman, Michael J., Ayala, Allison, Bressler, Neil M., Browning, David, Flaxel, Christina J., Glassman, Adam R., Jampol, Lee M., Stone, Thomas W.·2015·Ophthalmology

DOI 10.1016/j.ophtha.2014.08.047PMC PMC4520307

Open this paper in CoChat — free account

Abstract

Objective To report 5-year results from a previously reported trial evaluating intravitreal 0.5 mg ranibizumab with prompt versus deferred (for ≥24 weeks) focal/grid laser treatment for diabetic macular edema (DME).Design Multicenter, randomized clinical trial.Participants Among participants from the trial with 3 years of follow-up who subsequently consented to a 2-year extension and survived through 5 years, 124 (97%) and 111 (92%) completed the 5-year visit in the prompt and deferred groups, respectively.Methods Random assignment to ranibizumab every 4 weeks until no longer improving (with resumption if worsening) and prompt or deferred (≥24 weeks) focal/grid laser treatment.Main outcome measures Best-corrected visual acuity at the 5-year visit.Results The mean change in visual acuity letter score from baseline to the 5-year visit was +7.2 letters in the prompt laser group compared with +9.8 letters in the deferred laser group (mean difference, -2.6 letters; 95% confidence interval, -5.5 to +0.4 letters; P = 0.09). At the 5-year visit in the prompt versus deferred laser groups, there was vision loss of ≥10 letters in 9% versus 8%, an improvement of ≥10 letters in 46% versus 58%, and an improvement of ≥15 letters in 27% versus 38% of participants, respectively. From baseline to 5 years, 56% of participants in the deferred group did not receive laser. The median number of injections was 13 versus 17 in the prompt and deferral groups, including 54% and 45% receiving no injections during year 4 and 62% and 52% receiving no injections during year 5, respectively.Conclusions Five-year results suggest focal/grid laser treatment at the initiation of intravitreal ranibizumab is no better than deferring laser treatment for ≥24 weeks in eyes with DME involving the central macula with vision impairment. Although more than half of eyes in which laser treatment is deferred may avoid laser for at least 5 years, such eyes may require more injections to achieve these results when following this protocol. Most eyes treated with ranibizumab and either prompt or deferred laser maintain vision gains obtained by the first year through 5 years with little additional treatment after 3 years.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.ophtha.2014.08.047

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Linear Mixed Models for Longitudinal Data
Verbeke, G. (1997) · Lecture Notes in Statistics · doi:10.1007/978-1-4612-2294-1_3 · Cited by 3,506
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Martin, D. F., Maguire, M. G., Fine, S. L., Ying, G.-S., Jaffe, G. J., Grunwald, J. E., Toth, C., Redford, M., & Ferris, F. L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.03.053 · Cited by 1,715
Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema
Elman, M. J., Aiello, L. P., Beck, R. W., Bressler, N. M., Bressler, S. B., Edwards, A. R., Ferris, F. L., Friedman, S. M., Glassman, A. R., Miller, K. M., et al. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.02.031 · Cited by 1,431
Self-citation
The RESTORE Study
Mitchell, P., Bandello, F. M., Schmidt-Erfurth, U. M., Lang, G. E., Massin, P., Schlingemann, R. O., Sutter, F., Simader, C., Burian, G., Gerstner, O., et al. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.01.031 · Cited by 1,344
Expanded 2-Year Follow-up of Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema
Elman, M. J., Bressler, N. M., Qin, H., Beck, R. W., Ferris, F. L., Friedman, S. M., Glassman, A. R., Scott, I. U., Stockdale, C. R., & Sun, J. K. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2010.12.033 · Cited by 572
Self-citation
Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment
Elman, M. J., Qin, H., Aiello, L. P., Beck, R. W., Bressler, N. M., Ferris, F. L., Glassman, A. R., Maturi, R. K., & Melia, M. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.08.022 · Cited by 322
Self-citation
Mixed models for longitudinal data
Cecílio‐Fernandes, D., Tio, R. A., & Jaarsma, D. A. D. C. (2016) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 118
Reproducibility of Spectral-Domain Optical Coherence Tomography Retinal Thickness Measurements and Conversion to Equivalent Time-Domain Metrics in Diabetic Macular Edema
Bressler, S. B., Edwards, A. R., Chalam, K. V., Bressler, N. M., Glassman, A. R., Jaffe, G. J., Melia, M., Saggau, D. D., & Plous, O. Z. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2014.1698 · Cited by 105
Self-citation
Inference for the Marginal Model
(2009) · Springer series in statistics · doi:10.1007/978-1-4419-0300-6_6 · Cited by 6

Show all 10 references

Sorted by citations

VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
Diabetic retinopathy
Wong, T. Y., Cheung, C. M. G., Larsen, M., Sharma, S., & Simó, R. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.12 · Cited by 1,252
The progress in understanding and treatment of diabetic retinopathy
Stitt, A. W., Curtis, T. M., Chen, M., Medina, R. J., McKay, G. J., Jenkins, A. J., Gardiner, T. A., Lyons, T. J., Hammes, H., Simó, R., et al. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.08.001 · Cited by 1,202
Ten years of anti-vascular endothelial growth factor therapy
Ferrara, N., & Adamis, A. P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.17 · Cited by 1,074
Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials
Brown, D. M., Nguyen, Q. D., Marcus, D. M., Boyer, D. S., Patel, S. S., Feiner, L., Schlottmann, P. G., Rundle, A. C., Zhang, J., Rubio, R. G., et al. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.02.034 · Cited by 830
Intravitreal Aflibercept for Diabetic Macular Edema
Korobelnik, J., Diana, V., Schmidt-Erfurth, U. M., Boyer, D. S., Holz, F. G., Heier, J. S., Midena, E., Kaiser, P. K., Terasaki, H., Marcus, D. M., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.05.006 · Cited by 833
Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA)
Schmidt-Erfurth, U. M., García‐Arumí, J., Bandello, F. M., Berg, K., Chakravarthy, U., Gerendas, B. S., Jonas, J. B., Larsen, M., Tadayoni, R., & Loewenstein, A. (2017) · Ophthalmologica · doi:10.1159/000458539 · Cited by 728
Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration
Maguire, M. G., Martin, D. F., Ying, G.-S., Jaffe, G. J., Daniel, E., Grunwald, J. E., Toth, C. A., Ferris, F. L., & Fine, S. L. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.03.045 · Cited by 708
Global Estimates on the Number of People Blind or Visually Impaired by Diabetic Retinopathy: A Meta-analysis From 1990 to 2010
Leasher, J. L., Bourne, R., Flaxman, S. R., Jonas, J. B., Keeffe, J. E., Naidoo, K. S., Pesudovs, K., Price, H., White, R. A., Wong, T. Y., et al. (2016) · Diabetes Care · doi:10.2337/dc15-2171 · Cited by 658
Intravitreal Aflibercept for Diabetic Macular Edema
Brown, D. M., Schmidt-Erfurth, U. M., Diana, V., Holz, F. G., Boyer, D. S., Midena, E., Heier, J. S., Terasaki, H., Kaiser, P. K., Marcus, D. M., et al. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.06.017 · Cited by 625
Fully Automated Detection and Quantification of Macular Fluid in OCT Using Deep Learning
Schlegl, T., Waldstein, S. M., Bogunović, H., Endstraßer, F., Sadeghipour, A., Philip, A.-M., Podkowinski, D., Gerendas, B. S., Langs, G., & Schmidt-Erfurth, U. M. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.10.031 · Cited by 601
Diabetic Macular Edema: Pathophysiology and Novel Therapeutic Targets
Das, A., McGuire, P. G., & Rangasamy, S. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.03.024 · Cited by 559
Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives
Simó, R., & Hernández, C. (2013) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2013.09.005 · Cited by 506
Classification of diabetic retinopathy and diabetic macular edema
Wu, L. (2013) · World Journal of Diabetes · doi:10.4239/wjd.v4.i6.290 · Cited by 440
Intravitreal Aflibercept for Diabetic Macular Edema
Heier, J. S., Korobelnik, J., Brown, D. M., Schmidt-Erfurth, U. M., Diana, V., Midena, E., Boyer, D. S., Terasaki, H., Kaiser, P. K., Marcus, D. M., et al. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.07.032 · Cited by 436
Diabetic macular oedema
Tan, G. S. W., Cheung, N., Simó, R., Cheung, C. M. G., & Wong, T. Y. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30052-3 · Cited by 377
Early and Long-Term Responses to Anti–Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data
González, V. H., Campbell, J. H., Holekamp, N. M., Kiss, S., Loewenstein, A., Augustin, A. J., Ma, J., Ho, A. C., Patel, V. D., Whitcup, S. M., et al. (2016) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2016.09.012 · Cited by 353
Three-Year Outcomes of Individualized Ranibizumab Treatment in Patients with Diabetic Macular Edema
Schmidt-Erfurth, U. M., Lang, G. E., Holz, F. G., Schlingemann, R. O., Lanzetta, P., Massin, P., Gerstner, O., Bouazza, A. S., Shen, H., Osborne, A. R., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.11.041 · Cited by 324
A Randomized Clinical Trial of Intravitreal Bevacizumab versus Intravitreal Dexamethasone for Diabetic Macular Edema
Gillies, M. C., Lim, L. L., Campain, A. E., Quin, G., Salem, W., Li, J., Goodwin, S., Aroney, C., McAllister, I. L., & Fraser‐Bell, S. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.07.002 · Cited by 298
Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis
Virgili, G., Parravano, M., Evans, J. R., Gordon, I., & Lucenteforte, E. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007419.pub5 · Cited by 263
Diabetic retinopathy: loss of neuroretinal adaptation to the diabetic metabolic environment
Abcouwer, S. F., & Gardner, T. W. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12412 · Cited by 255
The Oxidative Stress and Mitochondrial Dysfunction during the Pathogenesis of Diabetic Retinopathy
Wu, M., Yiang, G., Lai, T.-T., & Li, C. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/3420187 · Cited by 264
The Evolving Treatment of Diabetic Retinopathy
Mansour, S. E., Browning, D. J., Wong, K., Flynn, H. W., & Bhavsar, A. R. (2020) · Clinical ophthalmology · doi:10.2147/opth.s236637 · Cited by 258
Self-citation
Novel approaches for treating diabetic retinopathy based on recent pathogenic evidence
Simó, R., & Hernández, C. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.04.003 · Cited by 247
Pericytes, an overlooked player in vascular pathobiology
Ferland-McCollough, D., Slater, S. C., Richard, J. S., Reni, C., & Mangialardi, G. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.11.008 · Cited by 238
Systemic Safety of Prolonged Monthly Anti–Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema
Avery, R. L., & Gordon, G. M. (2015) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2015.4070 · Cited by 218
Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment
Ross, E. L., Hutton, D. W., Stein, J. D., Bressler, N. M., Jampol, L. M., & Glassman, A. R. (2016) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2016.1669 · Cited by 215
Self-citation
Anti-vascular endothelial growth factor therapy for diabetic macular edema
Boyer, D. S., Hopkins, J. J., Sorof, J. M., & Ehrlich, J. S. (2013) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018813512360 · Cited by 200
Anti-vascular endothelial growth factor for diabetic macular oedema
Virgili, G., Parravano, M., Menchini, F., & Evans, J. R. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007419.pub4 · Cited by 188
Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema
Cai, S. C. S., & Bressler, N. M. (2017) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000424 · Cited by 183
Self-citation
Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis
Virgili, G., Parravano, M., Evans, J. R., Gordon, I., & Lucenteforte, E. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007419.pub6 · Cited by 183
Long-term Effects of Therapy with Ranibizumab on Diabetic Retinopathy Severity and Baseline Risk Factors for Worsening Retinopathy
Ip, M. S., Domalpally, A., Sun, J. K., & Ehrlich, J. S. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.08.048 · Cited by 181
The REVEAL Study
Ishibashi, T., Li, X., Koh, A., Lai, T. Y. Y., Lee, F.-L., Lee, W., Ma, Z., Ohji, M., Tan, N., Bok, S., et al. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.02.006 · Cited by 176
Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study
Prünte, C. F., Fajnkuchen, F., Mahmood, S., Ricci, F., Hatz, K. B., Studnička, J., Bezlyak, V., Parikh, S., Stubbings, W. J., Wenzel, A., et al. (2015) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2015-307249 · Cited by 170
Real-world Outcomes of Anti–Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema in the United States
Ciulla, T. A., Bracha, P., Pollack, J. S., & Williams, D. F. (2018) · Ophthalmology Retina · doi:10.1016/j.oret.2018.06.004 · Cited by 162
Treatment of diabetic retinopathy: Recent advances and unresolved challenges
Stewart, M. W. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i16.333 · Cited by 166
The role of inflammation in diabetic eye disease
Mesquida, M., Drawnel, F., & Fauser, S. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00750-7 · Cited by 159
Outcomes with As-Needed Ranibizumab after Initial Monthly Therapy
Boyer, D. S., Nguyen, Q. D., Brown, D. M., Basu, K., & Ehrlich, J. S. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.08.006 · Cited by 149
Laser Therapy in the Treatment of Diabetic Retinopathy and Diabetic Macular Edema
Everett, L. A., & Paulus, Y. M. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01403-6 · Cited by 149
Five-Year Outcomes of Ranibizumab With Prompt or Deferred Laser Versus Laser or Triamcinolone Plus Deferred Ranibizumab for Diabetic Macular Edema
Bressler, S. B., Glassman, A. R., Almukhtar, T., Bressler, N. M., Ferris, F. L., Googe, J. M., Gupta, S. K., Jampol, L. M., Melia, M., & Wells, J. A. (2016) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.12.025 · Cited by 139
Self-citation
Ocular Anti-VEGF Therapy for Diabetic Retinopathy: Overview of Clinical Efficacy and Evolving Applications
Cheung, N., Wong, I. Y., & Wong, T. Y. (2014) · Diabetes Care · doi:10.2337/dc13-1990 · Cited by 149
Effect of Intravitreous Anti–Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy
Maturi, R. K., Glassman, A. R., Josic, K., Antoszyk, A. N., Blodi, B. A., Jampol, L. M., Marcus, D. M., Martin, D. F., Melia, M., Salehi-Had, H., et al. (2021) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2021.0606 · Cited by 142
Self-citation
Diabetic Retinopathy and Diabetic Macular Edema
Cohen, S. R., & Gardner, T. W. (2015) · Developments in ophthalmology · doi:10.1159/000438970 · Cited by 141
SUBVISIBLE RETINAL LASER THERAPY
Lavinsky, D., Sramek, C., Wang, J. Y., Huie, P., Dalal, R., Mandel, Y., & Palanker, D. (2013) · Retina · doi:10.1097/iae.0b013e3182993edc · Cited by 132
Management of pseudophakic cystoid macular edema
Guo, S., Patel, S. N., Baumrind, B. R., Johnson, K. S., Levinsohn, D., Marcus, E., Tannen, B. L., Roy, M. S., Bhagat, N., & Zarbin, M. A. (2014) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2014.08.005 · Cited by 120
Diabetic retinopathy screening in the emerging era of artificial intelligence
Grauslund, J. (2022) · Diabetologia · doi:10.1007/s00125-022-05727-0 · Cited by 133
Early Response to Anti–Vascular Endothelial Growth Factor and Two-Year Outcomes Among Eyes With Diabetic Macular Edema in Protocol T
Bressler, N. M., Beaulieu, W. T., Maguire, M. G., Glassman, A. R., Blinder, K. J., Bressler, S. B., González, V. H., Jampol, L. M., Melia, M., Sun, J. K., et al. (2018) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2018.07.030 · Cited by 114
Self-citation
Involvement of Cytokines in the Pathogenesis of Diabetic Macular Edema
Noma, H., Yasuda, K., & Shimura, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073427 · Cited by 115
Management Paradigms for Diabetic Macular Edema
Mitchell, P., & Wong, T. Y. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.11.012 · Cited by 103
Underuse of the Health Care System by Persons With Diabetes Mellitus and Diabetic Macular Edema in the United States
Bressler, N. M., Varma, R., Doan, Q. V., Gleeson, M. L., Danese, M. D., Bower, J. K., Selvin, E., Dolan, C., Fine, J. T., Colman, S. S., et al. (2013) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2013.6426 · Cited by 100
Self-citation
Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy
Hussain, R. M., & Ciulla, T. A. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1131265 · Cited by 97
Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration
Khachigian, L. M., Liew, G., Teo, K. Y. C., Wong, T. Y., & Mitchell, P. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-03937-7 · Cited by 98
Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further?
Uludağ, G., Hassan, M., Matsumiya, W., Pham, B. H., Chea, S., Than, N. T. T., Hien, D. L., Akhavanrezayat, A., Halim, M. S., Diana, V., et al. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2100694 · Cited by 97
The Diabetic Retinopathy Clinical Research Network (DRCR.net) and Its Contributions to the Treatment of Diabetic Retinopathy
Sun, J. K., & Jampol, L. M. (2019) · Ophthalmic Research · doi:10.1159/000502779 · Cited by 89
Self-citation
Randomized Trial of Treat and Extend Ranibizumab with and without Navigated Laser for Diabetic Macular Edema
Payne, J. F., Wykoff, C. C., Clark, W. L., Bruce, B. B., Boyer, D. S., & Brown, D. M. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.09.021 · Cited by 87
Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature
Ashraf, M., Souka, A., & Adelman, R. A. (2016) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2016-308388 · Cited by 85
Diabetic Retinopathy: Animal Models, Therapies, and Perspectives
Cai, X., & McGinnis, J. F. (2016) · Journal of Diabetes Research · doi:10.1155/2016/3789217 · Cited by 85
Predictive Factors for the Progression of Diabetic Macular Ischemia
Sim, D. A., Keane, P. A., Zarranz‐Ventura, J., Bunce, C., Fruttiger, M., Patel, P. J., Tufail, A., & Egan, C. A. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.05.033 · Cited by 84
Quantification of Fluid Resolution and Visual Acuity Gain in Patients With Diabetic Macular Edema Using Deep Learning
Roberts, P. K., Vogl, W., Gerendas, B. S., Glassman, A. R., Bogunović, H., Jampol, L. M., & Schmidt-Erfurth, U. M. (2020) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2020.2457 · Cited by 83
Self-citation
Viewing the choroid: where we stand, challenges and contradictions in diabetic retinopathy and diabetic macular oedema
Campos, A., Campos, E. J., Martins, J., Ambrósio, A. F., & da Silva, R. M. (2016) · Acta Ophthalmologica · doi:10.1111/aos.13210 · Cited by 83
Diabetic macular ischaemia- a new therapeutic target?
Cheung, C. M. G., Fawzi, A. A., Teo, K. Y. C., Fukuyama, H., Sen, S., Tsai, W.-S., & Sivaprasad, S. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.101033 · Cited by 84
Anti-VEGF for the Management of Diabetic Macular Edema
Stefanini, F. R., Badaró, E., Falabella, P., Koss, M., Farah, M. E., & Maia, M. (2014) · Journal of Immunology Research · doi:10.1155/2014/632307 · Cited by 81
ASSOCIATION BETWEEN EARLY ANATOMIC RESPONSE TO ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY AND LONG-TERM OUTCOME IN DIABETIC MACULAR EDEMA
Dugel, P. U., Campbell, J. H., Kiss, S., Loewenstein, A., Shih, V., Xu, X., Holekamp, N. M., Augustin, A. J., Ho, A. C., González, V. H., et al. (2018) · Retina · doi:10.1097/iae.0000000000002110 · Cited by 79
Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice
Maloney, M. H., Payne, S. R., Herrin, J. S., Sangaralingham, L. R., Shah, N. D., & Barkmeier, A. J. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.07.062 · Cited by 78
Repeated Intravitreous Ranibizumab Injections for Diabetic Macular Edema and the Risk of Sustained Elevation of Intraocular Pressure or the Need for Ocular Hypotensive Treatment
Bressler, S. B., Almukhtar, T., Bhorade, A. M., Bressler, N. M., Glassman, A. R., Huang, S. S., Jampol, L. M., Kim, J. E., & Melia, M. (2015) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2015.186 · Cited by 75
Self-citation
Diabetic retinopathy screening guidelines in India
Raman, R., Ramasamy, K., Rajalakshmi, R., Sivaprasad, S., & Natarajan, S. (2020) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_667_20 · Cited by 77
AQUEOUS HUMOR CYTOKINE LEVELS AS BIOMARKERS OF DISEASE SEVERITY IN DIABETIC MACULAR EDEMA
Hillier, R. J., Ojaimi, E., Wong, D. T., Mak, M. Y. K., Berger, A. R., Kohly, R. P., Kertes, P. J., Forooghian, F., Boyd, S. R., Eng, K. T., et al. (2016) · Retina · doi:10.1097/iae.0000000000001210 · Cited by 77
RANIBIZUMAB PLUS PROMPT OR DEFERRED LASER FOR DIABETIC MACULAR EDEMA IN EYES WITH VITRECTOMY BEFORE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY
Bressler, S. B., Melia, M., Glassman, A. R., Almukhtar, T., Jampol, L. M., Shami, M., Berger, B. B., & Bressler, N. M. (2015) · Retina · doi:10.1097/iae.0000000000000617 · Cited by 77
Self-citation
Cost-Effectiveness of Treatment of Diabetic Macular Edema
Pershing, S., Enns, E. A., Matesic, B., Owens, D. K., & Goldhaber‐Fiebert, J. D. (2014) · Annals of Internal Medicine · doi:10.7326/m13-0768 · Cited by 73
Subthreshold micropulse laser reduces anti-VEGF injection burden in patients with diabetic macular edema
Moisseiev, E., Abbassi, S., Thinda, S., Yoon, J., Yiu, G. C., & Morse, L. S. (2017) · European Journal of Ophthalmology · doi:10.5301/ejo.5001000 · Cited by 73
Vascular endothelial growth factor and diabetic macular edema
Lally, D. R., Shah, C. P., & Heier, J. S. (2016) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2016.03.010 · Cited by 74
Efficacy of Anti-VEGF and Laser Photocoagulation in the Treatment of Visual Impairment due to Diabetic Macular Edema: A Systematic Review and Network Meta-Analysis
Régnier, S. A., Malcolm, W., Allen, F., Wright, J., & Bezlyak, V. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102309 · Cited by 71
Complications of Intravitreal Injections in Patients with Diabetes
Shikari, H., Silva, P. S., & Sun, J. K. (2014) · Seminars in Ophthalmology · doi:10.3109/08820538.2014.962167 · Cited by 71
Diabetic Macular Edema: Current Understanding, Pharmacologic Treatment Options, and Developing Therapie
Miller, K. M., & Fortun, J. A. (2018) · Asia-Pacific Journal of Ophthalmology · doi:10.22608/apo.2017529 · Cited by 71
Diabetic macular oedema: pathophysiology, management challenges and treatment resistance
Bahrami, B., Zhu, M., Hong, T., & Chang, A. (2016) · Diabetologia · doi:10.1007/s00125-016-3974-8 · Cited by 69
Randomized Trial of Treat and Extend Ranibizumab With and Without Navigated Laser Versus Monthly Dosing for Diabetic Macular Edema: TREX-DME 2-Year Outcomes
Payne, J. F., Wykoff, C. C., Clark, W. L., Bruce, B. B., Boyer, D. S., Brown, D. M., Payne, J. F., Clark, W. L., Wells, J. A., Johnson, D., et al. (2019) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2019.02.005 · Cited by 69
Corticosteroids for diabetic macular edema
Wu, L., Chawan-Saad, J., Wu, M. B. H., & Wu, A. (2019) · Taiwan Journal of Ophthalmology · doi:10.4103/tjo.tjo_68_19 · Cited by 67
Global reported endophthalmitis risk following intravitreal injections of anti-VEGF: a literature review and analysis
Schaal, S., Sigford, D. K., Reddy, S., & Mollineaux, C. (2015) · Clinical ophthalmology · doi:10.2147/opth.s77067 · Cited by 67
DETECTION OF CLINICALLY UNSUSPECTED RETINAL NEOVASCULARIZATION WITH WIDE-FIELD OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY
You, Q. S., Guo, Y., Wang, J., Wei, X., Camino, A., Zang, P., Flaxel, C. J., Bailey, S. T., Huang, D., Jia, Y., et al. (2019) · Retina · doi:10.1097/iae.0000000000002487 · Cited by 66
Self-citation
Loss to Follow-up After Intravitreal Anti–Vascular Endothelial Growth Factor Injections in Patients with Diabetic Macular Edema
Gao, X., Obeid, A., Aderman, C. M., Talcott, K. E., Ali, F. S., Adam, M. K., Rovner, B. W., Hyman, L., Ho, A. C., & Hsu, J. (2018) · Ophthalmology Retina · doi:10.1016/j.oret.2018.11.002 · Cited by 64
Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion
Brown, D. M., Ou, W. C., Wong, T. P., Kim, R. Y., Croft, D. E., & Wykoff, C. C. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2017.11.026 · Cited by 63
A review of therapies for diabetic macular oedema and rationale for combination therapy
Amoaku, W. M. K., Saker, S., & Stewart, E. A. (2015) · Eye · doi:10.1038/eye.2015.110 · Cited by 63
Association of Compounded Bevacizumab With Postinjection Endophthalmitis
VanderBeek, B. L., Bonaffini, S. G., & Ma, L. (2015) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2015.2556 · Cited by 63
Correlation Between Reflectivity of Subretinal Fluid in OCT Images and Concentration of Intravitreal VEGF in Eyes With Diabetic Macular Edema
Sonoda, S., Sakamoto, T., Shirasawa, M., Yamashita, T., Otsuka, H., & Terasaki, H. (2013) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.13-12382 · Cited by 63
Diabetic Retinopathy: Battling the Global Epidemic
Das, A. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-21031 · Cited by 65
The United Kingdom Diabetic Retinopathy Electronic Medical Record Users Group, Report 1: baseline characteristics and visual acuity outcomes in eyes treated with intravitreal injections of ranibizumab for diabetic macular oedema
Egan, C. A., Zhu, H., Lee, A., Sim, D. A., Mitry, D., Bailey, C., Johnston, R. L., Chakravarthy, U., Denniston, A. K., Tufail, A., et al. (2016) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2016-309313 · Cited by 63
Cost Effectiveness of Treatments for Diabetic Retinopathy: A Systematic Literature Review
Maniadakis, N., & Konstantakopoulou, E. (2019) · PharmacoEconomics · doi:10.1007/s40273-019-00800-w · Cited by 63
CHANGES IN DIABETIC RETINOPATHY SEVERITY WHEN TREATING DIABETIC MACULAR EDEMA WITH RANIBIZUMAB
Bressler, S. B., Odia, I., Glassman, A. R., Danis, R. P., Grover, S., Hampton, G. R., Jampol, L. M., Maguire, M. G., & Melia, M. (2018) · Retina · doi:10.1097/iae.0000000000002302 · Cited by 61
Self-citation
MicroRNA-126: a promising novel biomarker in peripheral blood for diabetic retinopathy
Qin, L.-L., An, M., Liu, Y., Xu, H., & Lu, Z.-Q. (2017) · International Journal of Ophthalmology · doi:10.18240/ijo.2017.04.05 · Cited by 60
Automatic detection of non-perfusion areas in diabetic macular edema from fundus fluorescein angiography for decision making using deep learning
Jin, K., Pan, X., You, K., Wu, J., Liu, Z., Cao, J., Lou, L., Xu, Y., Su, Z., Yao, K., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-71622-6 · Cited by 60
Indocyanine-green-guided targeted laser photocoagulation of capillary macroaneurysms in macular oedema: a pilot study
Pâques, M., Philippakis, E., Bonnet, C., Falah, S., Scheer, S., Zwillinger, S., Girmens, J., & Dupas, B. (2016) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2015-308142 · Cited by 60
Management of diabetic macular edema in Japan: a review and expert opinion
Terasaki, H., Ogura, Y., Kitano, S., Sakamoto, T., Murata, T., Hirakata, A., & Ishibashi, T. (2017) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-017-0537-6 · Cited by 61
Targeting VE-PTP phosphatase protects the kidney from diabetic injury
Carota, I. A., Kenig-Kozlovsky, Y., Onay, T., Scott, R. P., Thomson, B. R., Souma, T., Bartlett, C. S., Li, Y., Procissi, D., Ramirez, V., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20180009 · Cited by 60
The Early Treatment Diabetic Retinopathy Study historical review and relevance to today's management of diabetic macular edema
Relhan, N., & Flynn, H. W. (2017) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000362 · Cited by 59
Intravitreal Ranibizumab Therapy for Diabetic Macular Edema in Routine Practice: Two-Year Real-Life Data from a Non-interventional, Multicenter Study in Germany
Ziemssen, F., Wachtlin, J., Kuehlewein, L., Gamulescu, M., Bertelmann, T., Feucht, N., Voegeler, J., Koch, M., Liakopoulos, S., Schmitz-Valckenberg, S., et al. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0513-2 · Cited by 59
Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis
Virgili, G., Curran, K., Lucenteforte, E., Pető, T., & Parravano, M. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007419.pub7 · Cited by 65
New Diagnostic and Therapeutic Approaches for Preventing the Progression of Diabetic Retinopathy
Park, Y. G., & Roh, Y. (2015) · Journal of Diabetes Research · doi:10.1155/2016/1753584 · Cited by 58
Anti–Vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema
Jampol, L. M., Glassman, A. R., Bressler, N. M., Wells, J. A., & Ayala, A. R. (2016) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2016.3698 · Cited by 58
Self-citation
Ranibizumab in the Treatment of Diabetic Macular Edema: A Review of the Current Status, Unmet Needs, and Emerging Challenges
Dervenis, N., Mikropoulou, A. M., Tranos, P., & Dervenis, P. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0548-1 · Cited by 58
Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: A post hoc analysis of Protocol I data
Sadda, S. R., Campbell, J. H., Dugel, P. U., Holekamp, N. M., Kiss, S., Loewenstein, A., Augustin, A. J., Shih, V., Xu, X., Wykoff, C. C., et al. (2019) · Eye · doi:10.1038/s41433-019-0522-z · Cited by 57

Authors: Elman, M. J., Ayala, A., Bressler, N. M., Browning, D., Flaxel, C. J., Glassman, A. R., Jampol, L. M., & Stone, T. W.
Affiliations: Elman Retina Group (US)
Jaeb Center for Health Research (US)
Johns Hopkins University (US)
Charlotte Eye Ear Nose & Throat Associates (US)
Northwestern University (US)
Retina Associates of Kentucky (US)
Corresponding author: Ayala, Allison
ORCID: Elman, Michael J.
Ayala, Allison
Bressler, Neil M.
Browning, David
Flaxel, Christina J.
Glassman, Adam R.
Jampol, Lee M.
Venue: Ophthalmology
Publisher: Elsevier BV
Published: 2015-02
Volume: 122
Issue: 2
Pages: 375-381
ISSN: 0161-6420 (ISSN-L)
DOI: 10.1016/j.ophtha.2014.08.047
PMC: PMC4520307
OpenAlex: W1980342089
Cited by: 562
References: 10
Citations by year: 2026: 8 · 2025: 18 · 2024: 22 · 2023: 20 · 2022: 35 · 2021: 39 · 2020: 55 · 2019: 41 · 2018: 45 · 2017: 79 · 2016: 72 · 2015: 73
FWCI: 79.09
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Ophthalmology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Eye Institute (EY14231, EY-14229, EY18817, EY023207, U10EY018817, U10EY014229, U10EY023207, U10EY014231, UG1EY014231)
Topics: Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Keywords: diabetic macular edema, ranibizumab, intravitreal injection, best-corrected visual acuity, long-term visual outcomes, anti-VEGF therapy, vision loss, treatment duration extension, retinal laser treatment, anti-angiogenic therapy, treatment burden reduction
MeSH terms: Ranibizumab, Aged, Combined Modality Therapy, Diabetic Retinopathy, Female, Humans, Macular Edema, Male, Middle Aged, Visual Acuity, Treatment Outcome, Laser Coagulation, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Intravitreal Injections, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: 5-Year Randomized Trial Results

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks